nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP1A1—liver cancer	0.32	1	CbGaD
Lansoprazole—CYP1B1—Doxorubicin—liver cancer	0.0736	0.209	CbGbCtD
Lansoprazole—ABCG2—Sorafenib—liver cancer	0.0576	0.163	CbGbCtD
Lansoprazole—ABCG2—Doxorubicin—liver cancer	0.035	0.0992	CbGbCtD
Lansoprazole—CYP2C8—Sorafenib—liver cancer	0.0307	0.0871	CbGbCtD
Lansoprazole—CYP2C19—Sorafenib—liver cancer	0.0258	0.073	CbGbCtD
Lansoprazole—CYP1A2—Sorafenib—liver cancer	0.0238	0.0674	CbGbCtD
Lansoprazole—CYP2C9—Sorafenib—liver cancer	0.0214	0.0607	CbGbCtD
Lansoprazole—ABCB1—Sorafenib—liver cancer	0.0208	0.0589	CbGbCtD
Lansoprazole—CYP2D6—Sorafenib—liver cancer	0.0196	0.0555	CbGbCtD
Lansoprazole—ABCB1—Doxorubicin—liver cancer	0.0126	0.0358	CbGbCtD
Lansoprazole—CYP3A4—Sorafenib—liver cancer	0.0124	0.0353	CbGbCtD
Lansoprazole—CYP2D6—Doxorubicin—liver cancer	0.0119	0.0337	CbGbCtD
Lansoprazole—CYP3A4—Doxorubicin—liver cancer	0.00755	0.0214	CbGbCtD
Lansoprazole—Thiabendazole—CYP1A1—liver cancer	0.00262	0.636	CrCbGaD
Lansoprazole—Rabeprazole—CYP1A1—liver cancer	0.000825	0.2	CrCbGaD
Lansoprazole—Omeprazole—CYP1A1—liver cancer	0.000672	0.163	CrCbGaD
Lansoprazole—Dehydration—Doxorubicin—liver cancer	0.000158	0.000864	CcSEcCtD
Lansoprazole—Eosinophilia—Epirubicin—liver cancer	0.000157	0.000859	CcSEcCtD
Lansoprazole—Liver function test abnormal—Doxorubicin—liver cancer	0.000157	0.000858	CcSEcCtD
Lansoprazole—Dry skin—Doxorubicin—liver cancer	0.000156	0.000852	CcSEcCtD
Lansoprazole—Pancreatitis—Epirubicin—liver cancer	0.000155	0.000851	CcSEcCtD
Lansoprazole—Vomiting—Sorafenib—liver cancer	0.000155	0.000849	CcSEcCtD
Lansoprazole—Hypokalaemia—Doxorubicin—liver cancer	0.000155	0.000846	CcSEcCtD
Lansoprazole—Angina pectoris—Epirubicin—liver cancer	0.000154	0.000845	CcSEcCtD
Lansoprazole—Rash—Sorafenib—liver cancer	0.000154	0.000842	CcSEcCtD
Lansoprazole—Dermatitis—Sorafenib—liver cancer	0.000154	0.000841	CcSEcCtD
Lansoprazole—Breast disorder—Doxorubicin—liver cancer	0.000153	0.00084	CcSEcCtD
Lansoprazole—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000153	0.000837	CcSEcCtD
Lansoprazole—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000153	0.000837	CcSEcCtD
Lansoprazole—Headache—Sorafenib—liver cancer	0.000153	0.000837	CcSEcCtD
Lansoprazole—Bronchitis—Epirubicin—liver cancer	0.000153	0.000835	CcSEcCtD
Lansoprazole—Nasopharyngitis—Doxorubicin—liver cancer	0.000152	0.000831	CcSEcCtD
Lansoprazole—Pancytopenia—Epirubicin—liver cancer	0.000151	0.000824	CcSEcCtD
Lansoprazole—Gastritis—Doxorubicin—liver cancer	0.00015	0.000822	CcSEcCtD
Lansoprazole—Muscular weakness—Doxorubicin—liver cancer	0.00015	0.00082	CcSEcCtD
Lansoprazole—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00015	0.00082	CcSEcCtD
Lansoprazole—Dysuria—Epirubicin—liver cancer	0.000148	0.000812	CcSEcCtD
Lansoprazole—Neutropenia—Epirubicin—liver cancer	0.000148	0.000812	CcSEcCtD
Lansoprazole—Abdominal distension—Doxorubicin—liver cancer	0.000148	0.000808	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Epirubicin—liver cancer	0.000147	0.000807	CcSEcCtD
Lansoprazole—Dysphagia—Doxorubicin—liver cancer	0.000147	0.000803	CcSEcCtD
Lansoprazole—Influenza—Doxorubicin—liver cancer	0.000147	0.000803	CcSEcCtD
Lansoprazole—Asthma—Doxorubicin—liver cancer	0.000147	0.000803	CcSEcCtD
Lansoprazole—Pollakiuria—Epirubicin—liver cancer	0.000146	0.000802	CcSEcCtD
Lansoprazole—Eosinophilia—Doxorubicin—liver cancer	0.000145	0.000795	CcSEcCtD
Lansoprazole—Nausea—Sorafenib—liver cancer	0.000145	0.000793	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Epirubicin—liver cancer	0.000145	0.000792	CcSEcCtD
Lansoprazole—Weight increased—Epirubicin—liver cancer	0.000144	0.00079	CcSEcCtD
Lansoprazole—Pancreatitis—Doxorubicin—liver cancer	0.000144	0.000787	CcSEcCtD
Lansoprazole—Hyperglycaemia—Epirubicin—liver cancer	0.000143	0.000783	CcSEcCtD
Lansoprazole—Angina pectoris—Doxorubicin—liver cancer	0.000143	0.000782	CcSEcCtD
Lansoprazole—Pneumonia—Epirubicin—liver cancer	0.000142	0.000778	CcSEcCtD
Lansoprazole—Infestation—Epirubicin—liver cancer	0.000141	0.000774	CcSEcCtD
Lansoprazole—Infestation NOS—Epirubicin—liver cancer	0.000141	0.000774	CcSEcCtD
Lansoprazole—Bronchitis—Doxorubicin—liver cancer	0.000141	0.000772	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00014	0.000767	CcSEcCtD
Lansoprazole—Pancytopenia—Doxorubicin—liver cancer	0.000139	0.000763	CcSEcCtD
Lansoprazole—Renal failure—Epirubicin—liver cancer	0.000139	0.000761	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Epirubicin—liver cancer	0.000139	0.000759	CcSEcCtD
Lansoprazole—Stomatitis—Epirubicin—liver cancer	0.000138	0.000754	CcSEcCtD
Lansoprazole—Jaundice—Epirubicin—liver cancer	0.000138	0.000754	CcSEcCtD
Lansoprazole—Conjunctivitis—Epirubicin—liver cancer	0.000137	0.000752	CcSEcCtD
Lansoprazole—Urinary tract infection—Epirubicin—liver cancer	0.000137	0.000752	CcSEcCtD
Lansoprazole—Dysuria—Doxorubicin—liver cancer	0.000137	0.000751	CcSEcCtD
Lansoprazole—Neutropenia—Doxorubicin—liver cancer	0.000137	0.000751	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000136	0.000746	CcSEcCtD
Lansoprazole—Sweating—Epirubicin—liver cancer	0.000136	0.000742	CcSEcCtD
Lansoprazole—Pollakiuria—Doxorubicin—liver cancer	0.000136	0.000742	CcSEcCtD
Lansoprazole—Haematuria—Epirubicin—liver cancer	0.000135	0.000738	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Doxorubicin—liver cancer	0.000134	0.000733	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Epirubicin—liver cancer	0.000134	0.000732	CcSEcCtD
Lansoprazole—Weight increased—Doxorubicin—liver cancer	0.000134	0.000731	CcSEcCtD
Lansoprazole—Epistaxis—Epirubicin—liver cancer	0.000133	0.00073	CcSEcCtD
Lansoprazole—Sinusitis—Epirubicin—liver cancer	0.000133	0.000726	CcSEcCtD
Lansoprazole—Hyperglycaemia—Doxorubicin—liver cancer	0.000132	0.000724	CcSEcCtD
Lansoprazole—Agranulocytosis—Epirubicin—liver cancer	0.000132	0.000722	CcSEcCtD
Lansoprazole—Pneumonia—Doxorubicin—liver cancer	0.000132	0.00072	CcSEcCtD
Lansoprazole—Infestation NOS—Doxorubicin—liver cancer	0.000131	0.000716	CcSEcCtD
Lansoprazole—Infestation—Doxorubicin—liver cancer	0.000131	0.000716	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.00013	0.00071	CcSEcCtD
Lansoprazole—Bradycardia—Epirubicin—liver cancer	0.000129	0.000707	CcSEcCtD
Lansoprazole—Renal failure—Doxorubicin—liver cancer	0.000129	0.000704	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Doxorubicin—liver cancer	0.000128	0.000702	CcSEcCtD
Lansoprazole—Jaundice—Doxorubicin—liver cancer	0.000128	0.000698	CcSEcCtD
Lansoprazole—Stomatitis—Doxorubicin—liver cancer	0.000128	0.000698	CcSEcCtD
Lansoprazole—Rhinitis—Epirubicin—liver cancer	0.000127	0.000696	CcSEcCtD
Lansoprazole—Urinary tract infection—Doxorubicin—liver cancer	0.000127	0.000696	CcSEcCtD
Lansoprazole—Conjunctivitis—Doxorubicin—liver cancer	0.000127	0.000696	CcSEcCtD
Lansoprazole—Hepatitis—Epirubicin—liver cancer	0.000127	0.000695	CcSEcCtD
Lansoprazole—Hypoaesthesia—Epirubicin—liver cancer	0.000126	0.000691	CcSEcCtD
Lansoprazole—Pharyngitis—Epirubicin—liver cancer	0.000126	0.00069	CcSEcCtD
Lansoprazole—Sweating—Doxorubicin—liver cancer	0.000125	0.000686	CcSEcCtD
Lansoprazole—Urinary tract disorder—Epirubicin—liver cancer	0.000125	0.000686	CcSEcCtD
Lansoprazole—Oedema peripheral—Epirubicin—liver cancer	0.000125	0.000684	CcSEcCtD
Lansoprazole—Haematuria—Doxorubicin—liver cancer	0.000125	0.000683	CcSEcCtD
Lansoprazole—Connective tissue disorder—Epirubicin—liver cancer	0.000125	0.000683	CcSEcCtD
Lansoprazole—Urethral disorder—Epirubicin—liver cancer	0.000124	0.000681	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Doxorubicin—liver cancer	0.000124	0.000677	CcSEcCtD
Lansoprazole—Epistaxis—Doxorubicin—liver cancer	0.000123	0.000675	CcSEcCtD
Lansoprazole—Sinusitis—Doxorubicin—liver cancer	0.000123	0.000672	CcSEcCtD
Lansoprazole—Visual impairment—Epirubicin—liver cancer	0.000122	0.000669	CcSEcCtD
Lansoprazole—Agranulocytosis—Doxorubicin—liver cancer	0.000122	0.000668	CcSEcCtD
Lansoprazole—Erythema multiforme—Epirubicin—liver cancer	0.00012	0.000657	CcSEcCtD
Lansoprazole—Bradycardia—Doxorubicin—liver cancer	0.00012	0.000654	CcSEcCtD
Lansoprazole—Eye disorder—Epirubicin—liver cancer	0.000119	0.000649	CcSEcCtD
Lansoprazole—Tinnitus—Epirubicin—liver cancer	0.000118	0.000648	CcSEcCtD
Lansoprazole—Cardiac disorder—Epirubicin—liver cancer	0.000118	0.000645	CcSEcCtD
Lansoprazole—Rhinitis—Doxorubicin—liver cancer	0.000118	0.000644	CcSEcCtD
Lansoprazole—Hepatitis—Doxorubicin—liver cancer	0.000117	0.000643	CcSEcCtD
Lansoprazole—Hypoaesthesia—Doxorubicin—liver cancer	0.000117	0.00064	CcSEcCtD
Lansoprazole—Pharyngitis—Doxorubicin—liver cancer	0.000117	0.000638	CcSEcCtD
Lansoprazole—Urinary tract disorder—Doxorubicin—liver cancer	0.000116	0.000635	CcSEcCtD
Lansoprazole—Oedema peripheral—Doxorubicin—liver cancer	0.000116	0.000633	CcSEcCtD
Lansoprazole—Connective tissue disorder—Doxorubicin—liver cancer	0.000115	0.000632	CcSEcCtD
Lansoprazole—Angiopathy—Epirubicin—liver cancer	0.000115	0.00063	CcSEcCtD
Lansoprazole—Urethral disorder—Doxorubicin—liver cancer	0.000115	0.00063	CcSEcCtD
Lansoprazole—Immune system disorder—Epirubicin—liver cancer	0.000115	0.000628	CcSEcCtD
Lansoprazole—Mediastinal disorder—Epirubicin—liver cancer	0.000114	0.000626	CcSEcCtD
Lansoprazole—Chills—Epirubicin—liver cancer	0.000114	0.000623	CcSEcCtD
Lansoprazole—Arrhythmia—Epirubicin—liver cancer	0.000113	0.000621	CcSEcCtD
Lansoprazole—Visual impairment—Doxorubicin—liver cancer	0.000113	0.000619	CcSEcCtD
Lansoprazole—Alopecia—Epirubicin—liver cancer	0.000112	0.000614	CcSEcCtD
Lansoprazole—Mental disorder—Epirubicin—liver cancer	0.000111	0.000609	CcSEcCtD
Lansoprazole—Erythema multiforme—Doxorubicin—liver cancer	0.000111	0.000608	CcSEcCtD
Lansoprazole—Erythema—Epirubicin—liver cancer	0.00011	0.000605	CcSEcCtD
Lansoprazole—Malnutrition—Epirubicin—liver cancer	0.00011	0.000605	CcSEcCtD
Lansoprazole—Eye disorder—Doxorubicin—liver cancer	0.00011	0.000601	CcSEcCtD
Lansoprazole—Tinnitus—Doxorubicin—liver cancer	0.00011	0.000599	CcSEcCtD
Lansoprazole—Cardiac disorder—Doxorubicin—liver cancer	0.000109	0.000597	CcSEcCtD
Lansoprazole—Flatulence—Epirubicin—liver cancer	0.000109	0.000596	CcSEcCtD
Lansoprazole—Tension—Epirubicin—liver cancer	0.000108	0.000593	CcSEcCtD
Lansoprazole—Dysgeusia—Epirubicin—liver cancer	0.000108	0.000592	CcSEcCtD
Lansoprazole—Nervousness—Epirubicin—liver cancer	0.000107	0.000587	CcSEcCtD
Lansoprazole—Back pain—Epirubicin—liver cancer	0.000107	0.000585	CcSEcCtD
Lansoprazole—Angiopathy—Doxorubicin—liver cancer	0.000107	0.000583	CcSEcCtD
Lansoprazole—Muscle spasms—Epirubicin—liver cancer	0.000106	0.000581	CcSEcCtD
Lansoprazole—Immune system disorder—Doxorubicin—liver cancer	0.000106	0.000581	CcSEcCtD
Lansoprazole—Mediastinal disorder—Doxorubicin—liver cancer	0.000106	0.000579	CcSEcCtD
Lansoprazole—Chills—Doxorubicin—liver cancer	0.000105	0.000577	CcSEcCtD
Lansoprazole—Arrhythmia—Doxorubicin—liver cancer	0.000105	0.000574	CcSEcCtD
Lansoprazole—Vision blurred—Epirubicin—liver cancer	0.000104	0.00057	CcSEcCtD
Lansoprazole—Alopecia—Doxorubicin—liver cancer	0.000104	0.000568	CcSEcCtD
Lansoprazole—Mental disorder—Doxorubicin—liver cancer	0.000103	0.000563	CcSEcCtD
Lansoprazole—Ill-defined disorder—Epirubicin—liver cancer	0.000103	0.000561	CcSEcCtD
Lansoprazole—Malnutrition—Doxorubicin—liver cancer	0.000102	0.00056	CcSEcCtD
Lansoprazole—Erythema—Doxorubicin—liver cancer	0.000102	0.00056	CcSEcCtD
Lansoprazole—Anaemia—Epirubicin—liver cancer	0.000102	0.000559	CcSEcCtD
Lansoprazole—Agitation—Epirubicin—liver cancer	0.000102	0.000556	CcSEcCtD
Lansoprazole—Flatulence—Doxorubicin—liver cancer	0.000101	0.000551	CcSEcCtD
Lansoprazole—Tension—Doxorubicin—liver cancer	0.0001	0.000549	CcSEcCtD
Lansoprazole—Dysgeusia—Doxorubicin—liver cancer	0.0001	0.000548	CcSEcCtD
Lansoprazole—Malaise—Epirubicin—liver cancer	9.96e-05	0.000545	CcSEcCtD
Lansoprazole—Nervousness—Doxorubicin—liver cancer	9.93e-05	0.000543	CcSEcCtD
Lansoprazole—Vertigo—Epirubicin—liver cancer	9.93e-05	0.000543	CcSEcCtD
Lansoprazole—Syncope—Epirubicin—liver cancer	9.91e-05	0.000542	CcSEcCtD
Lansoprazole—Leukopenia—Epirubicin—liver cancer	9.89e-05	0.000541	CcSEcCtD
Lansoprazole—Back pain—Doxorubicin—liver cancer	9.89e-05	0.000541	CcSEcCtD
Lansoprazole—Muscle spasms—Doxorubicin—liver cancer	9.83e-05	0.000538	CcSEcCtD
Lansoprazole—Palpitations—Epirubicin—liver cancer	9.76e-05	0.000534	CcSEcCtD
Lansoprazole—Loss of consciousness—Epirubicin—liver cancer	9.71e-05	0.000532	CcSEcCtD
Lansoprazole—Cough—Epirubicin—liver cancer	9.64e-05	0.000528	CcSEcCtD
Lansoprazole—Vision blurred—Doxorubicin—liver cancer	9.64e-05	0.000527	CcSEcCtD
Lansoprazole—Convulsion—Epirubicin—liver cancer	9.57e-05	0.000524	CcSEcCtD
Lansoprazole—Hypertension—Epirubicin—liver cancer	9.54e-05	0.000522	CcSEcCtD
Lansoprazole—Ill-defined disorder—Doxorubicin—liver cancer	9.49e-05	0.000519	CcSEcCtD
Lansoprazole—Anaemia—Doxorubicin—liver cancer	9.45e-05	0.000517	CcSEcCtD
Lansoprazole—Chest pain—Epirubicin—liver cancer	9.41e-05	0.000515	CcSEcCtD
Lansoprazole—Myalgia—Epirubicin—liver cancer	9.41e-05	0.000515	CcSEcCtD
Lansoprazole—Arthralgia—Epirubicin—liver cancer	9.41e-05	0.000515	CcSEcCtD
Lansoprazole—Agitation—Doxorubicin—liver cancer	9.4e-05	0.000514	CcSEcCtD
Lansoprazole—Anxiety—Epirubicin—liver cancer	9.37e-05	0.000513	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	9.34e-05	0.000511	CcSEcCtD
Lansoprazole—Discomfort—Epirubicin—liver cancer	9.29e-05	0.000509	CcSEcCtD
Lansoprazole—Malaise—Doxorubicin—liver cancer	9.22e-05	0.000505	CcSEcCtD
Lansoprazole—Dry mouth—Epirubicin—liver cancer	9.2e-05	0.000504	CcSEcCtD
Lansoprazole—Vertigo—Doxorubicin—liver cancer	9.19e-05	0.000503	CcSEcCtD
Lansoprazole—Syncope—Doxorubicin—liver cancer	9.17e-05	0.000502	CcSEcCtD
Lansoprazole—Leukopenia—Doxorubicin—liver cancer	9.15e-05	0.000501	CcSEcCtD
Lansoprazole—Confusional state—Epirubicin—liver cancer	9.09e-05	0.000498	CcSEcCtD
Lansoprazole—Palpitations—Doxorubicin—liver cancer	9.04e-05	0.000494	CcSEcCtD
Lansoprazole—Oedema—Epirubicin—liver cancer	9.02e-05	0.000494	CcSEcCtD
Lansoprazole—Anaphylactic shock—Epirubicin—liver cancer	9.02e-05	0.000494	CcSEcCtD
Lansoprazole—Loss of consciousness—Doxorubicin—liver cancer	8.99e-05	0.000492	CcSEcCtD
Lansoprazole—Infection—Epirubicin—liver cancer	8.96e-05	0.00049	CcSEcCtD
Lansoprazole—Cough—Doxorubicin—liver cancer	8.92e-05	0.000488	CcSEcCtD
Lansoprazole—Shock—Epirubicin—liver cancer	8.87e-05	0.000486	CcSEcCtD
Lansoprazole—Convulsion—Doxorubicin—liver cancer	8.86e-05	0.000485	CcSEcCtD
Lansoprazole—Nervous system disorder—Epirubicin—liver cancer	8.84e-05	0.000484	CcSEcCtD
Lansoprazole—Thrombocytopenia—Epirubicin—liver cancer	8.83e-05	0.000483	CcSEcCtD
Lansoprazole—Hypertension—Doxorubicin—liver cancer	8.83e-05	0.000483	CcSEcCtD
Lansoprazole—Tachycardia—Epirubicin—liver cancer	8.8e-05	0.000482	CcSEcCtD
Lansoprazole—Skin disorder—Epirubicin—liver cancer	8.76e-05	0.000479	CcSEcCtD
Lansoprazole—Hyperhidrosis—Epirubicin—liver cancer	8.72e-05	0.000477	CcSEcCtD
Lansoprazole—Chest pain—Doxorubicin—liver cancer	8.7e-05	0.000476	CcSEcCtD
Lansoprazole—Arthralgia—Doxorubicin—liver cancer	8.7e-05	0.000476	CcSEcCtD
Lansoprazole—Myalgia—Doxorubicin—liver cancer	8.7e-05	0.000476	CcSEcCtD
Lansoprazole—Anxiety—Doxorubicin—liver cancer	8.67e-05	0.000475	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	8.64e-05	0.000473	CcSEcCtD
Lansoprazole—Discomfort—Doxorubicin—liver cancer	8.6e-05	0.000471	CcSEcCtD
Lansoprazole—Anorexia—Epirubicin—liver cancer	8.6e-05	0.00047	CcSEcCtD
Lansoprazole—Dry mouth—Doxorubicin—liver cancer	8.51e-05	0.000466	CcSEcCtD
Lansoprazole—Hypotension—Epirubicin—liver cancer	8.43e-05	0.000461	CcSEcCtD
Lansoprazole—Confusional state—Doxorubicin—liver cancer	8.41e-05	0.00046	CcSEcCtD
Lansoprazole—Anaphylactic shock—Doxorubicin—liver cancer	8.34e-05	0.000457	CcSEcCtD
Lansoprazole—Oedema—Doxorubicin—liver cancer	8.34e-05	0.000457	CcSEcCtD
Lansoprazole—Infection—Doxorubicin—liver cancer	8.29e-05	0.000454	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Epirubicin—liver cancer	8.22e-05	0.00045	CcSEcCtD
Lansoprazole—Shock—Doxorubicin—liver cancer	8.21e-05	0.000449	CcSEcCtD
Lansoprazole—Nervous system disorder—Doxorubicin—liver cancer	8.18e-05	0.000448	CcSEcCtD
Lansoprazole—Thrombocytopenia—Doxorubicin—liver cancer	8.17e-05	0.000447	CcSEcCtD
Lansoprazole—Insomnia—Epirubicin—liver cancer	8.16e-05	0.000446	CcSEcCtD
Lansoprazole—Tachycardia—Doxorubicin—liver cancer	8.14e-05	0.000446	CcSEcCtD
Lansoprazole—Skin disorder—Doxorubicin—liver cancer	8.11e-05	0.000444	CcSEcCtD
Lansoprazole—Paraesthesia—Epirubicin—liver cancer	8.1e-05	0.000443	CcSEcCtD
Lansoprazole—Hyperhidrosis—Doxorubicin—liver cancer	8.07e-05	0.000441	CcSEcCtD
Lansoprazole—Dyspnoea—Epirubicin—liver cancer	8.04e-05	0.00044	CcSEcCtD
Lansoprazole—Somnolence—Epirubicin—liver cancer	8.02e-05	0.000439	CcSEcCtD
Lansoprazole—Anorexia—Doxorubicin—liver cancer	7.95e-05	0.000435	CcSEcCtD
Lansoprazole—Dyspepsia—Epirubicin—liver cancer	7.94e-05	0.000434	CcSEcCtD
Lansoprazole—Decreased appetite—Epirubicin—liver cancer	7.84e-05	0.000429	CcSEcCtD
Lansoprazole—Hypotension—Doxorubicin—liver cancer	7.8e-05	0.000427	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Epirubicin—liver cancer	7.79e-05	0.000426	CcSEcCtD
Lansoprazole—Fatigue—Epirubicin—liver cancer	7.78e-05	0.000426	CcSEcCtD
Lansoprazole—Pain—Epirubicin—liver cancer	7.71e-05	0.000422	CcSEcCtD
Lansoprazole—Constipation—Epirubicin—liver cancer	7.71e-05	0.000422	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Doxorubicin—liver cancer	7.6e-05	0.000416	CcSEcCtD
Lansoprazole—Insomnia—Doxorubicin—liver cancer	7.55e-05	0.000413	CcSEcCtD
Lansoprazole—Paraesthesia—Doxorubicin—liver cancer	7.49e-05	0.00041	CcSEcCtD
Lansoprazole—Dyspnoea—Doxorubicin—liver cancer	7.44e-05	0.000407	CcSEcCtD
Lansoprazole—Feeling abnormal—Epirubicin—liver cancer	7.43e-05	0.000407	CcSEcCtD
Lansoprazole—Somnolence—Doxorubicin—liver cancer	7.42e-05	0.000406	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Epirubicin—liver cancer	7.37e-05	0.000404	CcSEcCtD
Lansoprazole—Dyspepsia—Doxorubicin—liver cancer	7.35e-05	0.000402	CcSEcCtD
Lansoprazole—Decreased appetite—Doxorubicin—liver cancer	7.25e-05	0.000397	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Doxorubicin—liver cancer	7.2e-05	0.000394	CcSEcCtD
Lansoprazole—Fatigue—Doxorubicin—liver cancer	7.19e-05	0.000394	CcSEcCtD
Lansoprazole—Urticaria—Epirubicin—liver cancer	7.16e-05	0.000392	CcSEcCtD
Lansoprazole—Constipation—Doxorubicin—liver cancer	7.14e-05	0.000391	CcSEcCtD
Lansoprazole—Pain—Doxorubicin—liver cancer	7.14e-05	0.000391	CcSEcCtD
Lansoprazole—Body temperature increased—Epirubicin—liver cancer	7.13e-05	0.00039	CcSEcCtD
Lansoprazole—Abdominal pain—Epirubicin—liver cancer	7.13e-05	0.00039	CcSEcCtD
Lansoprazole—Feeling abnormal—Doxorubicin—liver cancer	6.88e-05	0.000376	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Doxorubicin—liver cancer	6.82e-05	0.000373	CcSEcCtD
Lansoprazole—Hypersensitivity—Epirubicin—liver cancer	6.64e-05	0.000364	CcSEcCtD
Lansoprazole—Urticaria—Doxorubicin—liver cancer	6.63e-05	0.000363	CcSEcCtD
Lansoprazole—Body temperature increased—Doxorubicin—liver cancer	6.6e-05	0.000361	CcSEcCtD
Lansoprazole—Abdominal pain—Doxorubicin—liver cancer	6.6e-05	0.000361	CcSEcCtD
Lansoprazole—Asthenia—Epirubicin—liver cancer	6.47e-05	0.000354	CcSEcCtD
Lansoprazole—Pruritus—Epirubicin—liver cancer	6.38e-05	0.000349	CcSEcCtD
Lansoprazole—Diarrhoea—Epirubicin—liver cancer	6.17e-05	0.000338	CcSEcCtD
Lansoprazole—Hypersensitivity—Doxorubicin—liver cancer	6.15e-05	0.000336	CcSEcCtD
Lansoprazole—Asthenia—Doxorubicin—liver cancer	5.99e-05	0.000328	CcSEcCtD
Lansoprazole—Dizziness—Epirubicin—liver cancer	5.96e-05	0.000326	CcSEcCtD
Lansoprazole—Pruritus—Doxorubicin—liver cancer	5.9e-05	0.000323	CcSEcCtD
Lansoprazole—Vomiting—Epirubicin—liver cancer	5.73e-05	0.000314	CcSEcCtD
Lansoprazole—Diarrhoea—Doxorubicin—liver cancer	5.71e-05	0.000312	CcSEcCtD
Lansoprazole—Rash—Epirubicin—liver cancer	5.69e-05	0.000311	CcSEcCtD
Lansoprazole—Dermatitis—Epirubicin—liver cancer	5.68e-05	0.000311	CcSEcCtD
Lansoprazole—Headache—Epirubicin—liver cancer	5.65e-05	0.000309	CcSEcCtD
Lansoprazole—Dizziness—Doxorubicin—liver cancer	5.52e-05	0.000302	CcSEcCtD
Lansoprazole—Nausea—Epirubicin—liver cancer	5.36e-05	0.000293	CcSEcCtD
Lansoprazole—Vomiting—Doxorubicin—liver cancer	5.31e-05	0.00029	CcSEcCtD
Lansoprazole—Rash—Doxorubicin—liver cancer	5.26e-05	0.000288	CcSEcCtD
Lansoprazole—Dermatitis—Doxorubicin—liver cancer	5.26e-05	0.000288	CcSEcCtD
Lansoprazole—Headache—Doxorubicin—liver cancer	5.23e-05	0.000286	CcSEcCtD
Lansoprazole—Nausea—Doxorubicin—liver cancer	4.96e-05	0.000271	CcSEcCtD
Lansoprazole—ABCB1—Metabolism—CRABP1—liver cancer	9.54e-06	6.79e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	9.54e-06	6.79e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—GSTM1—liver cancer	9.53e-06	6.78e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—liver cancer	9.52e-06	6.77e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	9.46e-06	6.73e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ALDOB—liver cancer	9.43e-06	6.71e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	9.37e-06	6.67e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ALDOB—liver cancer	9.35e-06	6.65e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—ALB—liver cancer	9.34e-06	6.64e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PSMD10—liver cancer	9.31e-06	6.62e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PSMA4—liver cancer	9.31e-06	6.62e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	9.3e-06	6.62e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CD—liver cancer	9.28e-06	6.6e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—MTHFR—liver cancer	9.26e-06	6.59e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CB—liver cancer	9.25e-06	6.58e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—ALB—liver cancer	9.16e-06	6.52e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PPARA—liver cancer	9.09e-06	6.46e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GOT2—liver cancer	9.06e-06	6.44e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CYP1A1—liver cancer	9.04e-06	6.43e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CRABP1—liver cancer	8.99e-06	6.4e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTA4—liver cancer	8.96e-06	6.37e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CRABP1—liver cancer	8.92e-06	6.34e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	8.8e-06	6.26e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	8.76e-06	6.23e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTA2—liver cancer	8.73e-06	6.21e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	8.67e-06	6.17e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—ALB—liver cancer	8.56e-06	6.09e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—HPGDS—liver cancer	8.55e-06	6.08e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PSMA4—liver cancer	8.54e-06	6.07e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PSMD10—liver cancer	8.54e-06	6.07e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CYP2E1—liver cancer	8.51e-06	6.06e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	8.5e-06	6.05e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTA1—liver cancer	8.43e-06	5.99e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—MTHFR—liver cancer	8.43e-06	5.99e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—HPGDS—liver cancer	8.34e-06	5.94e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NAT2—liver cancer	8.33e-06	5.93e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GOT2—liver cancer	8.3e-06	5.91e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PPARA—liver cancer	8.27e-06	5.88e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	8.24e-06	5.87e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	8.16e-06	5.81e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CB—liver cancer	8.09e-06	5.75e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	8.03e-06	5.71e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	8.01e-06	5.7e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ALDOB—liver cancer	7.99e-06	5.68e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CPT1B—liver cancer	7.98e-06	5.67e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GLUL—liver cancer	7.98e-06	5.67e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CYCS—liver cancer	7.97e-06	5.67e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—HPGDS—liver cancer	7.86e-06	5.59e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	7.85e-06	5.59e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GOT1—liver cancer	7.82e-06	5.56e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GGT1—liver cancer	7.82e-06	5.56e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP2E1—liver cancer	7.81e-06	5.55e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—HPGDS—liver cancer	7.79e-06	5.54e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CG—liver cancer	7.78e-06	5.54e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	7.75e-06	5.51e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	7.74e-06	5.51e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NR1H4—liver cancer	7.69e-06	5.47e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	7.64e-06	5.44e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CRABP1—liver cancer	7.62e-06	5.42e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PSMA4—liver cancer	7.62e-06	5.42e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PSMD10—liver cancer	7.62e-06	5.42e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTA3—liver cancer	7.56e-06	5.38e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.56e-06	5.38e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PPARG—liver cancer	7.51e-06	5.34e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PSMA4—liver cancer	7.44e-06	5.29e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PSMD10—liver cancer	7.44e-06	5.29e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GOT2—liver cancer	7.41e-06	5.27e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYCS—liver cancer	7.3e-06	5.2e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GOT2—liver cancer	7.23e-06	5.15e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GGT1—liver cancer	7.17e-06	5.1e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GOT1—liver cancer	7.17e-06	5.1e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	7.09e-06	5.04e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CG—liver cancer	7.08e-06	5.04e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	7.06e-06	5.02e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GSTP1—liver cancer	7.02e-06	5e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PSMA4—liver cancer	7.01e-06	4.98e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PSMD10—liver cancer	7.01e-06	4.98e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP2E1—liver cancer	6.97e-06	4.96e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	6.97e-06	4.96e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PSMD10—liver cancer	6.95e-06	4.94e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PSMA4—liver cancer	6.95e-06	4.94e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—HMOX1—liver cancer	6.93e-06	4.93e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTA4—liver cancer	6.92e-06	4.92e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	6.86e-06	4.88e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CD—liver cancer	6.84e-06	4.87e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PPARG—liver cancer	6.83e-06	4.86e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GOT2—liver cancer	6.82e-06	4.85e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP2E1—liver cancer	6.8e-06	4.84e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GOT2—liver cancer	6.76e-06	4.81e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ALB—liver cancer	6.75e-06	4.8e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	6.75e-06	4.8e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTA2—liver cancer	6.74e-06	4.79e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—HPGDS—liver cancer	6.66e-06	4.74e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6.62e-06	4.71e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYCS—liver cancer	6.52e-06	4.64e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTA1—liver cancer	6.5e-06	4.63e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GSTM1—liver cancer	6.45e-06	4.59e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GSTP1—liver cancer	6.44e-06	4.58e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NAT2—liver cancer	6.43e-06	4.57e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	6.41e-06	4.56e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP2E1—liver cancer	6.41e-06	4.56e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GOT1—liver cancer	6.4e-06	4.55e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GGT1—liver cancer	6.4e-06	4.55e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYCS—liver cancer	6.36e-06	4.53e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP2E1—liver cancer	6.35e-06	4.52e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—HMOX1—liver cancer	6.35e-06	4.52e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GOT1—liver cancer	6.24e-06	4.44e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GGT1—liver cancer	6.24e-06	4.44e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CD—liver cancer	6.22e-06	4.43e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ALDOB—liver cancer	6.16e-06	4.39e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	6.15e-06	4.38e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ALB—liver cancer	6.14e-06	4.37e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	6.03e-06	4.29e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYCS—liver cancer	6e-06	4.27e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CB—liver cancer	5.96e-06	4.24e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.95e-06	4.24e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYCS—liver cancer	5.94e-06	4.23e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PSMA4—liver cancer	5.94e-06	4.22e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PSMD10—liver cancer	5.94e-06	4.22e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GSTM1—liver cancer	5.92e-06	4.21e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GOT1—liver cancer	5.88e-06	4.19e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GGT1—liver cancer	5.88e-06	4.19e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CRABP1—liver cancer	5.88e-06	4.18e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GOT1—liver cancer	5.83e-06	4.15e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GGT1—liver cancer	5.83e-06	4.15e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GOT2—liver cancer	5.77e-06	4.11e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTP1—liver cancer	5.75e-06	4.09e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—MTHFR—liver cancer	5.7e-06	4.06e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—HMOX1—liver cancer	5.67e-06	4.03e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CA—liver cancer	5.64e-06	4.01e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTP1—liver cancer	5.61e-06	3.99e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP1A1—liver cancer	5.61e-06	3.99e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PPARA—liver cancer	5.6e-06	3.98e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—HMOX1—liver cancer	5.53e-06	3.94e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP2E1—liver cancer	5.43e-06	3.86e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CB—liver cancer	5.42e-06	3.86e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTP1—liver cancer	5.29e-06	3.76e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTM1—liver cancer	5.28e-06	3.76e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.26e-06	3.74e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTP1—liver cancer	5.24e-06	3.73e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—MTHFR—liver cancer	5.23e-06	3.72e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—HMOX1—liver cancer	5.21e-06	3.71e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—HMOX1—liver cancer	5.17e-06	3.68e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTM1—liver cancer	5.15e-06	3.67e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—HPGDS—liver cancer	5.14e-06	3.66e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PPARA—liver cancer	5.13e-06	3.65e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYCS—liver cancer	5.08e-06	3.61e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.03e-06	3.58e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP1A1—liver cancer	5.01e-06	3.56e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GGT1—liver cancer	4.98e-06	3.55e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GOT1—liver cancer	4.98e-06	3.55e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CA—liver cancer	4.93e-06	3.51e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP1A1—liver cancer	4.89e-06	3.48e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTM1—liver cancer	4.86e-06	3.46e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTM1—liver cancer	4.82e-06	3.43e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CG—liver cancer	4.79e-06	3.41e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—MTHFR—liver cancer	4.67e-06	3.32e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PPARG—liver cancer	4.62e-06	3.29e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.61e-06	3.28e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—AKT1—liver cancer	4.61e-06	3.28e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP1A1—liver cancer	4.6e-06	3.28e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PSMA4—liver cancer	4.58e-06	3.26e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PSMD10—liver cancer	4.58e-06	3.26e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PPARA—liver cancer	4.58e-06	3.26e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP1A1—liver cancer	4.56e-06	3.25e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—MTHFR—liver cancer	4.56e-06	3.24e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTP1—liver cancer	4.48e-06	3.19e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PPARA—liver cancer	4.47e-06	3.18e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GOT2—liver cancer	4.46e-06	3.17e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—HMOX1—liver cancer	4.42e-06	3.14e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CG—liver cancer	4.39e-06	3.13e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—MTHFR—liver cancer	4.29e-06	3.05e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—MTHFR—liver cancer	4.26e-06	3.03e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PPARG—liver cancer	4.24e-06	3.02e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CD—liver cancer	4.21e-06	3e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PPARA—liver cancer	4.21e-06	3e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP2E1—liver cancer	4.19e-06	2.98e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PPARA—liver cancer	4.17e-06	2.97e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ALB—liver cancer	4.16e-06	2.96e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTM1—liver cancer	4.11e-06	2.93e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.11e-06	2.93e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—AKT1—liver cancer	4.03e-06	2.87e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CG—liver cancer	3.92e-06	2.79e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYCS—liver cancer	3.92e-06	2.79e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP1A1—liver cancer	3.9e-06	2.77e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CD—liver cancer	3.86e-06	2.75e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GOT1—liver cancer	3.85e-06	2.74e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GGT1—liver cancer	3.85e-06	2.74e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CG—liver cancer	3.83e-06	2.72e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ALB—liver cancer	3.81e-06	2.71e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PPARG—liver cancer	3.78e-06	2.69e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.75e-06	2.67e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PPARG—liver cancer	3.69e-06	2.63e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CB—liver cancer	3.67e-06	2.61e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—MTHFR—liver cancer	3.64e-06	2.59e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CA—liver cancer	3.63e-06	2.59e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CG—liver cancer	3.61e-06	2.57e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CG—liver cancer	3.58e-06	2.54e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PPARA—liver cancer	3.57e-06	2.54e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PPARG—liver cancer	3.48e-06	2.48e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTP1—liver cancer	3.46e-06	2.46e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PPARG—liver cancer	3.45e-06	2.45e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CD—liver cancer	3.45e-06	2.45e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—HMOX1—liver cancer	3.41e-06	2.42e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ALB—liver cancer	3.4e-06	2.42e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CB—liver cancer	3.37e-06	2.39e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CD—liver cancer	3.36e-06	2.39e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ALB—liver cancer	3.32e-06	2.36e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CA—liver cancer	3.31e-06	2.35e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.2e-06	2.28e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTM1—liver cancer	3.18e-06	2.26e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CD—liver cancer	3.17e-06	2.26e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CD—liver cancer	3.14e-06	2.24e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ALB—liver cancer	3.13e-06	2.23e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ALB—liver cancer	3.1e-06	2.21e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CG—liver cancer	3.06e-06	2.17e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP1A1—liver cancer	3.01e-06	2.14e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CB—liver cancer	3e-06	2.14e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—AKT1—liver cancer	2.97e-06	2.11e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PPARG—liver cancer	2.95e-06	2.1e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CB—liver cancer	2.93e-06	2.09e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—MTHFR—liver cancer	2.81e-06	2e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CB—liver cancer	2.76e-06	1.97e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PPARA—liver cancer	2.75e-06	1.96e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CB—liver cancer	2.74e-06	1.95e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AKT1—liver cancer	2.7e-06	1.92e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CD—liver cancer	2.69e-06	1.91e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ALB—liver cancer	2.65e-06	1.89e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CG—liver cancer	2.36e-06	1.68e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CB—liver cancer	2.34e-06	1.67e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PPARG—liver cancer	2.28e-06	1.62e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CA—liver cancer	2.24e-06	1.59e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CD—liver cancer	2.07e-06	1.47e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CA—liver cancer	2.05e-06	1.46e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ALB—liver cancer	2.05e-06	1.46e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CA—liver cancer	1.83e-06	1.3e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AKT1—liver cancer	1.83e-06	1.3e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CB—liver cancer	1.81e-06	1.29e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CA—liver cancer	1.79e-06	1.27e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CA—liver cancer	1.68e-06	1.2e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AKT1—liver cancer	1.68e-06	1.19e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CA—liver cancer	1.67e-06	1.19e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AKT1—liver cancer	1.5e-06	1.06e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AKT1—liver cancer	1.46e-06	1.04e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CA—liver cancer	1.43e-06	1.02e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AKT1—liver cancer	1.38e-06	9.79e-06	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AKT1—liver cancer	1.36e-06	9.71e-06	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AKT1—liver cancer	1.17e-06	8.29e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CA—liver cancer	1.1e-06	7.84e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AKT1—liver cancer	9e-07	6.4e-06	CbGpPWpGaD
